Timing
Purchase and sale flow
PurchasesSales
Stock, pipeline and biotech catalyst intelligence
Reported ownership activity
Activity signal
Reported purchases exceed sales by $33.8KOption exercises, awards, and grants are separated from open-market direction.Timing
Composition
Concentration
| Insider trading | Relationship | Date | Transaction | Cost | Shares | Value | Shares total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Wettig Thane | CEO | Nov 17 '25 | Buy | $9.10 | 2,700 | $24,570 | 24,939 | Nov 17 04:42 PM |
| Wettig Thane | CEO | Nov 13 '25 | Buy | $9.18 | 1,000 | $9,180 | 22,239 | Nov 17 04:42 PM |
Transactions may include sales, purchases, grants, and option exercises. Directional charts count only purchases and sales; follow the Form 4 link to verify the original SEC filing.
Company profile
FibroGen Inc is a biotechnology company in the healthcare sector.
Company profile compiled from available company records. Catalyst dates can change and should be confirmed against the linked primary source.
Page updated Aug 23, 2026 · Yahoo quotes cached for one minute; reference data may be used when a live field is unavailable.